ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019
Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Evaluating eight smoking metrics for modelling survival in non-small cell lung cancer.Cancer epidemiology · 2026Pooled it
- First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis.Frontiers in oncology · 2024Pooled it
- Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer.Cancer research and treatment · 2023Trial
- Racial difference in BMI and lung cancer diagnosis: analysis of the National Lung Screening Trial.BMC cancer · 2022Trial
- Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study.BMC medicine · 2022Trial
- Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.BMC cancer · 2021Trial
- Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- Predicting 5-Year Mortality in Non-Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study.JMIR medical informatics · 2026Article
- Will We Need a Novel Heuristic in Resectable Lung Cancer?: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Graph convolutional network-derived pathomics and clinical integration for predicting chemoimmunotherapy response in advanced lung squamous cell carcinoma: a multicenter study.Journal of translational medicine · 2026Article
- Retrospective study on the tolerability using a four-cycle completion in elderly patients with extensive-stage small-cell lung cancer: a body mass index-based analysis.Translational lung cancer research · 2026Article
- Body mass index and fasting insulin predict survival and EGFR-TKI benefit in Stage IV lung adenocarcinoma.Frontiers in oncology · 2026Article
- Association between body-mass index change and lung cancer risk in Korea: nested case-control study.BMC cancer · 2025Observational
- Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer.Translational lung cancer research · 2025Article
- Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) database.Translational lung cancer research · 2025Article
- The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review.Cancers · 2025Review
- Integrating Clinical and Imaging Markers for Survival Prediction in Advanced NSCLC Treated with EGFR-TKIs.Cancers · 2025Article
- Relationship between preoperative body mass index and overall mortality in patients who have undergone lobectomy for lung cancer.World journal of surgical oncology · 2025Article
- Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
37 authors at 20 institutions in 7 countries.
Daniel ShepshelovichDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre; University of Toronto, Toronto, Ontario, Canada; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Lin LuDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Aline FaresDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre; University of Toronto, Toronto, Ontario, Canada.
Ping YangMayo Clinic, Rochester, Minnesota.
David ChristianiEnvironmental Health Department, Harvard TH Chan School of Public Health and Harvard Medical School, Boston, Massachusetts.
Jie ZhangDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Kouya ShiraishiDivision of Genome Biology, National Cancer Research Institute, Tokyo, Japan.
Brid M RyanCentre for Cancer Research, National Institutes of Health, Bethesda, Maryland.
Chu ChenProgram in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology and Department of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Ann G SchwartzBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Adonina TardonIUOPA, University of Oviedo and CIBERESP, Oviedo, Spain.
Xifeng WuUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Matthew B SchabathH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
M Dawn TeareUniversity of Sheffield, Sheffield, United Kingdom.
Loic Le MarchandUniversity of Hawaii Cancer Centre, Honolulu, Hawaii.
Zuo-Feng ZhangUniversity of California Los Angeles School of Public Health, California.
John K FieldThe Roy Castle Lung Cancer Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, United Kingdom.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nancy DiaoEnvironmental Health Department, Harvard TH Chan School of Public Health and Harvard Medical School, Boston, Massachusetts.
Juntao XieDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Takashi KohnoDivision of Genome Biology, National Cancer Research Institute, Tokyo, Japan.
Curtis C HarrisCentre for Cancer Research, National Institutes of Health, Bethesda, Maryland.
Angela S WenzlaffBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Guillermo Fernandez-TardonIUOPA, University of Oviedo and CIBERESP, Oviedo, Spain.
Yuanqing YeUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Fiona TaylorUniversity of Sheffield, Sheffield, United Kingdom.
Lynne R WilkensUniversity of Hawaii Cancer Centre, Honolulu, Hawaii.
Michael DaviesThe Roy Castle Lung Cancer Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, United Kingdom.
Yi LiuPLA Hospital, Beijing, China.
Matt J BarnettCancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gary E GoodmanSwedish Cancer Institute, Seattle, Washington.
Hal MorgensternDepartments of Epidemiology and Environmental Health Sciences, School of Public Health and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
Bernd HolleczekSaarland Cancer Registry, Saarbrücken, Germany.
M Catherine BrownDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre; University of Toronto, Toronto, Ontario, Canada.
Geoffrey LiuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre; University of Toronto, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. Electronic address: geoffrey.liu@uhn.ca.
Rayjean J HungDivision of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre · CAHarvard University · USNational Institutes of Health · USThe University of Texas MD Anderson Cancer Center · USUniversidad de Oviedo · ESUniversity of Liverpool · GBUniversity of Sheffield · GBUniversity of Toronto · CACancer Center of Hawaii · USFred Hutch Cancer Center · USFudan University Shanghai Cancer Center · CNGerman Cancer Research Center · DEKrebsregister Saarland · DEMayo Clinic · USMoffitt Cancer Center · USPLA 306 Hospital · CNPublic Health Ontario · CASwedish Medical Center · USTel Aviv University · ILThe Barbara Ann Karmanos Cancer Institute · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MTumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MPrecision Medicine of CancerZIABC011492 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HARRIS, CURTIS · 2013 to 2025
$23.2MTHE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0MSPORE in Lung CancerP50CA119997 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GABRILOVICH, DMITRY I · 2008 to 2012
$11.0MStatistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9MGENETIC EPIDEMIOLOGY OF LUNG CANCERR01CA060691 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G. · 1995 to 2009
$6.2MAdenocarinoma of the Lung in WomenR01CA087895 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G · 2001 to 2005
$3.0MInfrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9MINFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8MStem Cell Selection &Expansion Via HOX Gene ActivationR01CA090833 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EMERSON, STEPHEN G · 2001 to 2010
$2.6MCCR NIH HHS HHSN261201300011CIntramural NIH HHS Z01 BC005480NCI NIH HHS P30 CA022453NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA119997NCI NIH HHS R01 CA060691NCI NIH HHS R01 CA087895NCI NIH HHS R01 CA090833NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS UM1 CA167462
Abstract
introductionThe relationships between morbid obesity, changes in body mass index (BMI) before cancer diagnosis, and lung cancer outcomes by histology (SCLC and NSCLC) have not been well studied.
methodsIndividual level data analysis was performed on 25,430 patients with NSCLC and 2787 patients with SCLC from 16 studies of the International Lung Cancer Consortium evaluating the association between various BMI variables and lung cancer overall survival, reported as adjusted hazard ratios (aHRs) from Cox proportional hazards models and adjusted penalized smoothing spline plots.
resultsOverall survival of NSCLC had putative U-shaped hazard ratio relationships with BMI based on spline plots: being underweight (BMI < 18.5 kg/m
conclusionsBoth being underweight or morbidly obese at time of diagnosis is associated with lower stage-specific survival in independent assessments of NSCLC and SCLC patients. In addition, a decrease in BMI at lung cancer diagnosis relative to early adulthood is a consistent marker of poor survival.
Indexed as
AdolescentAdultAgedAged, 80 and overBody Mass IndexCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedRisk FactorsSmall Cell Lung CarcinomaSurvival AnalysisYoung AdultBody mass indexLung cancerSurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.